47th week of 2010 patent applcation highlights part 40 |
Patent application number | Title | Published |
20100297599 | TRANSPARENT COOLING GEL - For cooling organs and tissues in transplantation medicine, only ice preparations are used so far which are not soft like a gel and are brought to the necessary degree of comminution by mechanically comminuting frozen, sterile, pyrogen-free isotonic infusion solutions, such as 5% glucose or 0.9% saline, with great effort. The lack of gel-like consistency of the preparations and the expensive production process are very disadvantageous. | 2010-11-25 |
20100297600 | Flooding dish and method for changing media in the dish in the preparation of mammalian specimen culture and for cryo-preservation, freezing, vitrification and the thawing and warming of such specimens - A tray assembly which may include a single well or a plurality of wells that will contain specimens for cryo-preservation, freezing, thawing, or warming. The assembly will include a structure whereby a sequence of different media solutions can be introduced into a well or wells in the assembly without the need to move the specimens and without disturbing an overlying oil layer which floats on top of the media solutions. The media solutions will be introduced into the specimen wells through adjunct passages which communicate with the interior of the wells. The adjunct passages will preferably be integral with the wells and will be formed at the same time the wells are formed. Thus manufacturing the assembly of this invention will be inexpensive and repetitive. The adjunct passages can be used to infuse different media solutions into the wells at different stages of the protocols in question. The wells can be inverted cones or pyramids in shape. This shape allows the infusion of sequential media solutions beneath the overlying oil layer, without disturbing the specimen and without significantly elevating the solution level in the wells. The conical or pyramidal shapes also enable the user to readily locate and handle the specimens because the specimens will always gravitate to the nadir of the conical or pyramidal bottom of the wells. This shape also allows the user to see any media level indices placed on the side walls of the wells. | 2010-11-25 |
20100297601 | Small volume and ultra speed colorimetric sensor - A sensor designed to accommodate an aqueous analyte sample having a volume of less than 1 μL and can be used to quantify the amount and concentration of such analyte through light reflectance or fiber-optic light reflectance. The sensor includes a reaction membrane and a fixed-volume sample chamber. The fixed-volume sample chamber acts to collect the sample and to secure such sample while it undergoes detection. The reaction membrane contains all of the chemicals and enzymes needed to cause a color reaction when contacted with the sample. The amount of analyte can be determined by light reflectance intensity. The sensor can be used with a meter for in-vitro clinical diagnosis and for patient self-monitoring of a physical condition, such as blood glucose levels. | 2010-11-25 |
20100297602 | Apparatus and method of contaminant detection - The present invention is a method and apparatus for contaminant detection of body parts, such as hands, and or their coverings, such as clean room suits or gloves, and small objects. Particularly, the method and apparatus involve collecting air samples containing aerosolized contaminate particles from the objects and analyzing the sample for presence of a contaminate. Aerosol lab-on-a-chip and/or electronic nose devices are utilized for the detection of contaminant particles. | 2010-11-25 |
20100297603 | ANALYTE-RELEASING BEADS AND USE THEREOF IN QUANTITATIVE ELISPOT OR FLUORISPOT ASSAY - The present invention relates to a method of quantifying analyte secreted by a cell or released from a drug delivery vehicle, typically by ELISpot or fluorispot assay. Quantification is possible through the use of an analyte-releasing reagent that includes a bead and the analyte releasably bound to the bead, or a container pre-spotted with analyte released from the reagent. The reagent or pre-spotted containers can be used to provide a standard curve for release of the analyte. By detecting analyte secreted by one or more cells or drug released by a drug delivery vehicle, and comparing the detected analyte to the standard curve, it is possible to quantify the amount of analyte released by the one or more cells or drug released by the drug delivery vehicle. Kits and reagents for practicing the methods of the present invention are also disclosed. | 2010-11-25 |
20100297604 | METHODS AND REAGENTS FOR VIRUS ISOLATION AND DETECTION - The present invention relates to reagents and methods used in virus isolation and analysis. | 2010-11-25 |
20100297605 | Screening method for prophylactic and/or therapeutic agent for disease accompanied by hepatitis c - Provided is a screening method being able to screen an agent useful for prevention and/or treatment of hepatitis C virus-related disease easily and efficiently and a prophylactic and/or therapeutic agent for hepatitis C virus-related disease obtained by the method. | 2010-11-25 |
20100297606 | IgG BINDING PEPTIDE - The present invention provides a peptide capable of specifically binding to human IgG. In particular, the present invention relates to a human IgG binding peptide tag of 11 to 16 amino acids in length, comprising at least an amino acid sequence of the formula I: | 2010-11-25 |
20100297607 | Reagents For HCV Antigen-Antibody Combination Assays - The present invention is directed to combination immunoassays, reagents and kits for simultaneous detection of HCV antigens and anti-HCV antibodies in a sample. The combination immunoassays of the present invention employ a non-ionic detergent that effectively exposes or releases the HCV core antigen from virions in a sample without interfering with the performance of other reagents such as the capture of anti-HCV antibodies by recombinant HCV antigens. | 2010-11-25 |
20100297608 | Systems and Methods for CMOS-Compatible Silicon Nano-Wire Sensors with Biochemical and Cellular Interfaces - The systems and methods described herein include a sensor for suitable for sensing chemical and biological substances. The sensor comprises a semiconductor layer formed in or on a substrate and a channel having nano-scale dimensions formed in the semiconductor layer, where the structure creates an electrically conducting pathway between a first contact and a second contact on the semiconductor layer. In certain preferred embodiments, the nano-scale channel has a trapezoidal cross-section with an effective width and exposed lateral faces, where the effective width is selected to have same order of magnitude as a Debye length (L | 2010-11-25 |
20100297609 | VIVO ISOTOPIC LABELING METHOD FOR QUANTITATIVE GLYCOMICS - The present invention relates to a method of isotopically labeling glycans and in facilitating high throughput quantitative/comparative analysis of glycomic compositions of biological cells. The method is applicable inter alia for identifying differentiated cells and their glycomic characteristics, differentiation conditions, disease and/or therapeutic progression, diagnosing disease states, determining drug activity, establishing manufacturing efficiencies and for determining the half-life of glycans in cells. | 2010-11-25 |
20100297610 | MOLECULARLY IMPRINTED POLYMERS FOR DETECTING HIV-1 - The invention described herein provides molecularly imprinted polymers (MIPs) that are capable of binding to virus, and methods for detecting and/or identifying specific virus particles utilizing Molecularly Imprinted Polymers (MIPs). The virus particles of the invention include HIV-1, HIV-2, HTLV-1, HTLV-2, HPV, HBV, and HCV. The methods of the invention comprise detecting all or part, including epitopes, of macromolecules associated with a virus. The macromolecules of the invention include proteins, glycoproteins (e.g., envelope glycoproteins), peptides, and polypeptides associated with said virus. The invention also provides for methods of diagnosing a subject infected with a virus utilizing MIPs, in addition to diagnostic kits. | 2010-11-25 |
20100297611 | Method and Device For Combined Detection Of Viral And Bacterial Infections - A lateral flow assay detects and differentiates between viral and bacterial infections. A combined point of care diagnostic device tests markers for viral infection and markers for bacterial infection, to effectively assist in the rapid differentiation of viral and bacterial infections. In one preferred embodiment, the bacterial marker is CRP. In another preferred embodiment, the viral marker is MxA. In some embodiments, it is unnecessary to lyse the cells in the sample prior to applying it to the device. | 2010-11-25 |
20100297612 | OPTIMIZED PROBES AND PRIMERS AND METHODS OF USING SAME FOR THE DETECTION, SCREENING, QUANTITATION, ISOLATION AND SEQUENCING OF CYTOMEGALOVIRUS AND EPSTEIN-BARR VIRUS - Described herein are primers and probes useful for detecting, screening, quantitating, isolating and sequencing CMV and EBV viral strains, and methods of using the described primers and probes. | 2010-11-25 |
20100297613 | Nucleic acid, amino acid encoded by said nucleic acid, probe comprising said nucleic acid or said amino acid, and screening method using said probe - A nucleic acid involved in the control of the biological clock comprising following (a) or (b):
| 2010-11-25 |
20100297614 | PROCESS FOR THE DETECTION OF CYTOSINE METHYLATIONS - The invention concerns a method for the detection of cytosine methylations in DNA and a kit for undertaking an assay according to the method of the invention. | 2010-11-25 |
20100297615 | EGFR MUTATIONS - The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment. | 2010-11-25 |
20100297616 | SITU HYBRIDISATION METHOD - There is provided an improved method of in situ hybridisation. In particular, a method of in situ hybridisation of biopolymer(s) in a sample of cells, with the proviso that the digestion of polypeptides is not performed. The method may be applicable to detection of different types of biopolymers, including detection of nucleic acids and polypeptides in the same sample. In particular, the method is for the detection of chromosomal abnormalities in uncultured amniotic cells. | 2010-11-25 |
20100297617 | PRIMER SET FOR AMPLIFYING NAT2 GENE, REAGENT FOR AMPLIFYING NAT2 GENE CONTAINING THE SAME, AND THE USES THEREOF - Primer sets for amplifying target regions containing sites to be detected in the NAT2 gene by a gene amplification method are provided, wherein the primer sets can amplify the regions specifically. Three pairs of primer sets are used including forward primers consisting of the base sequences of SEQ ID NOs: 7, 33, and 60 as well as reverse primers consisting of the base sequences of SEQ ID NOs: 18, 48 and 81, respectively. The use of these primer sets makes it possible to amplify three target regions including parts where three types of polymorphisms (NAT2*5, NAT2*6, and NAT2*7) of the NAT2 gene are generated, respectively, in the same reaction solution at the same time. | 2010-11-25 |
20100297618 | METHODS FOR DETERMINING A PROGNOSIS OF COLORECTAL CANCER - The invention provides methods for determining a prognosis of colorectal cancer in an individual comprising determining an A-type lamin status of an individual and using the A-type lamin status to determine the prognosis of the colorectal cancer, and more particularly for predicting outcomes of colorectal cancer in the individual such as the survival or mortality of the individual or the likelihood of recurrence of the colorectal cancer. Kits for use in carrying out these methods are also provided. | 2010-11-25 |
20100297619 | GENETIC PREDICTION OF SCHIZOPHRENIA SUSCEPTIBILITY - Provided are methods of determining the likelihood that a patient will be diagnosed with schizophrenia. | 2010-11-25 |
20100297620 | ACTIVATED PROTEASE INDICATOR - It is an object of the invention to provide novel approaches capable of detecting activated protease and also detecting protease activation on real time at a high sensitivity in a noninvasive manner. By the method for detecting activated protease of the invention, an indicator in a circular form comprising the C-half fragment of luciferase (Luc-C) and the N-half fragment of luciferase (Luc-N) linked together through a substrate peptide for a protease is introduced in an in vitro assay system or in cells. Upon digestion of the substrate peptide by the protease, Luc-N and Luc-C together reconstructs active luciferase, so that the activated protease can be detected by assaying the luminescence signal from the luciferase. | 2010-11-25 |
20100297621 | USE OF PRE-MRNA SPLICING IN PLATELET CELLS FOR THE DIAGNOSIS OF DISEASE - The invention relates to materials and procedures for identifying or using tissue factor (TF) pre-mRNA splicing, CIk 1 activity or TF-dependent coagulation in platelet cells for the diagnosis, prognosis, or prediction of a disease or disorder associated with disordered coagulation. Since activated platelets splice pre-mRNAs to generate inflammatory and thrombotic mediators that contribute to diseases such as sepsis and septic shock, (TF) pre-mRNA splicing in platelets is an indicator of inflammatory and thrombotic disease states. TF pre-mRNA splicing in platelets is correlated with sepsis, increased age (≧65), APACHE II score, and bacteremia. Thus, TF mRNA expression patterns in platelets may be used for the diagnosis, prognosis, or prediction of a disease or disorder associated with disordered coagulation, for example, patients that are at a higher risk for severe sepsis, organ failure, and death. | 2010-11-25 |
20100297622 | Method for high-throughput gene expression profile analysis - The present invention embraces a method for high-throughput gene profiling with high specificity and sensitivity. With this system, >1000 mRNA species can be co-amplified using gene-specific primers from a single cell. The primers are designed to amplify sequences of desirable length, which are in different exons. The exons can be either adjacent and separated by a large intron or include more than two exons. The amplified sequences are then analyzed by microarray with probes hybridizing to neighboring exons. | 2010-11-25 |
20100297623 | NOVEL HUMAN ssDNA BINDING PROTEINS AND METHODS OF CANCER DIAGNOSIS - A method for detecting transformed cells or tumour cells, a method for diagnosing or prognosing cancer or for assessing a predisposition to cancer, and kits for use in the methods are disclosed. The methods particularly involve the detection of overexpression of an ssDNA binding protein (SSB) or polypeptide comprising the following amino acid sequence: FX | 2010-11-25 |
20100297624 | Involvement of Lipid Kinase, and Signal Transduction Pathway Comprising Said Lipid Kinase, in Resistance to HER2-Targeting Therapy - The invention is related to a method for determining whether an individual suffering from cancer is at risk of exhibiting or acquiring a reduced response towards HER2-targeting therapy. In one aspect, the invention utilizes the activity of a signal transduction pathway modulated by a lipid kinase for determining said risk. | 2010-11-25 |
20100297625 | BIOMARKERS FOR PSYCHOSIS - The present invention relates generally to the diagnosis of psychosis, schizophrenia and bipolar disorder, including psychotic bipolar disorder. | 2010-11-25 |
20100297626 | Reagents, Methods, and Libraries for Bead-Based Sequencing - The present invention provides methods for determining a nucleic acid sequence by performing successive cycles of duplex extension along a single stranded template. The cycles comprise steps of extension, ligation, and, preferably, cleavage. In certain embodiments the methods make use of extension probes containing phosphorothiolate linkages and employ agents appropriate to cleave such linkages. In certain embodiments the methods make use of extension probes containing an abasic residue or a damaged base and employ agents appropriate to cleave linkages between a nucleoside and an abasic residue and/or agents appropriate to remove a damaged base from a nucleic acid. The invention provides methods of determining information about a sequence using at least two distinguishably labeled probe families. In certain embodiments the methods acquire less than 2 bits of information from each of a plurality of nucleotides in the template in each cycle. In certain embodiments the sequencing reactions are performed on templates attached to beads, which are immobilized in or on a semi-solid support. The invention further provides sets of labeled extension probes containing phosphorothiolate linkages or trigger residues that are suitable for use in the method. In addition, the invention includes performing multiple sequencing reactions on a single template by removing initializing oligonucleotides and extended strands and performing subsequent reactions using different initializing oligonucleotides. The invention further provides efficient methods for preparing templates, particularly for performing sequencing multiple different templates in parallel. The invention also provides methods for performing ligation and cleavage. The invention also provides new libraries of nucleic acid fragments containing paired tags, and methods of preparing microparticles having multiple different templates (e.g., containing paired tags) attached thereto and of sequencing the templates individually. The invention also provides automated sequencing systems, flow cells, image processing methods, and computer-readable media that store computer-executable instructions (e.g., to perform the image-processing methods) and/or sequence information. In certain embodiments the sequence information is stored in a database. | 2010-11-25 |
20100297627 | MicroRNA Diagnostics for Cancer - Disclosed are methods for detecting breast cancer or prostate cancer by measuring levels of miR-204 and miR-510 in samples. | 2010-11-25 |
20100297628 | Methods Of Producing And Sequencing Modified Polynucleotides - The present invention encompasses methods for producing a modified polynucleotide sequence that comprises a (e.g., one or more) phosphorothiolate linkage, methods for determining a polynucleotide sequence comprising a (e.g., one or more) phosphorothiolate linkage, and methods for separating forward and reverse extension products that comprise a (e.g., one or more) phosphorothiolate linkage. The invention also encompasses kits for producing and/or determining the sequence of a modified polynucleotide that comprises a (e.g., one or more) phosphorothiolate linkage. | 2010-11-25 |
20100297629 | NUCLEIC ACID SUPPORTED PROTEIN COMPLEMENTATION - The present invention is directed to novel methods for in vitro and in vivo detection of target nucleic acid molecules, including DNA and RNA targets, as well as nucleic acid analogues. The present invention is based on protein complementation, in which two individual polypeptides are inactive. When the two inactive polypeptide fragment are brought in close proximity during hybridization to a target nucleic acid, they re-associate into an active, detectable protein. | 2010-11-25 |
20100297630 | METHOD FOR THE SIMULTANEOUS DETECTION OF MULTIPLE NUCLEIC ACID SEQUENCES IN A SAMPLE - The invention is in the technical field of detecting nucleic acid sequences in a sample, such as the detection of pathogenic organisms in clinical samples. More specifically, the invention relates to the field of detecting an infection caused by a pathogenic organism such as a virus or a bacterium in a clinical specimen by means of amplifying and detecting specific nucleic acid sequences from said pathogenic organism. It provides a multiplex assay with the possibility to determine about 30 different target nucleic acid sequences in a single one-tube assay combined with real-time probe detection. The method employs multiplex ligation dependent Probe Amplification (MLPA) employing labelled primers in combination with labelled, probes and detection of the fluorescence. | 2010-11-25 |
20100297631 | Compositions and Methods For Detecting Histamine Related Disorders - The present invention generally relates to methods and compositions (e.g., assay kit) for the diagnosis of histamine related disorders. The invention also relates to a novel molecular target of histamine related disorders and the uses thereof for detecting or diagnosing such diseases, as well as to develop adapted and efficient therapeutic treatment thereof. The invention may be used in any mammalian subject, particularly human subjects. | 2010-11-25 |
20100297632 | UPREGULATION OF RACK-1 IN MELANOMA AND ITS USE AS A MARKER - The present invention concerns a method for diagnosing a melanoma in a mammal comprising the detection of the overexpression of RACK-1 protein in a melanocyte cell of said mammal, and the deduction of the presence of a melanoma from the overexpression of RACK-1 protein. The invention is also directed to a method for determining the tumoral status of a melanocyte cell of a mammal, comprising the detection of overexpression of RACK-1 protein in the melanocyte cell, and the deduction of the tumoral state of said cell from the overexpression of RACK-1 protein. | 2010-11-25 |
20100297633 | METHOD OF AMPLIFYING NUCLEIC ACID - The present invention provides a method for detecting a polymorphism or mutation in nucleic acid comprising a first phase to amplify or enrich for a sequence comprising a polymorphism or mutation and a second phase for detecting the polymorphism or mutation, wherein both phases are performed in the same reaction vessel. | 2010-11-25 |
20100297634 | GENE EXPRESSION SIGNATURES IN ENRICHED TUMOR CELL SAMPLES - The invention is embodied in methods for finding gene expression signatures of circulating melanoma cells, ovarian, breast, colorectal cancer cells, and circulating endothelial progenitor cells, which signatures are effective in distinguishing the circulating cancer cell from normal circulating cells and can also distinguish between different types of circulating cancer cells. | 2010-11-25 |
20100297635 | COLLECTION AND MEASUREMENT OF EXHALED PARTICLES - Particles are exhaled in the breath of animals. The nature and amounts of the particles can be indicative of certain medical conditions. They can therefore be collected, sorted according to size or mass and used in the diagnosis of one or more medical conditions. The invention provides a method and system for collecting and sorting exhaled particles and a method for diagnosis using said exhaled particles. | 2010-11-25 |
20100297636 | CC2D2A GENE MUTATIONS ASSOCIATED WITH JOUBERT SYNDROME AND DIAGNOSTIC METHODS FOR IDENTIFYING THE SAME - The present invention provides a method of screening a subject for mutations in the CC2D2A gene that are associated with Joubert syndrome, an autosomal recessive form of mental retardation. The present invention also provides proteins that are associated with Joubert syndrome including proteins comprising an amino acid sequence that terminates in DHEGGSGMES (SEQ ID NO: 1). Also provided are nucleotide sequences encoding such proteins and methods of screening subjects to identify nucleotide sequences or proteins associated with Joubert syndrome. | 2010-11-25 |
20100297637 | PRIMER FOR AMPLIFICATION OF RRNA OR BACTERIUM BELONGING TO THE GENUS LEGIONELLA, DETECTION METHOD, AND DETECTION KIT - To detect a bacterium belonging to the genus | 2010-11-25 |
20100297638 | MOLECULAR ADAPTORS - The invention relates to transmembrane protein pore for use in detecting a analyte in a sample. The pore comprises a molecular adaptor that facilitates an interaction between the pore and the analyte. The adaptor is covalently attached to the pore in an orientation that allows the analyte to be detected using the pore. | 2010-11-25 |
20100297639 | QUANTITATIVE/SEMI-QUANTITATIVE MEASUREMENT OF EPOR ON CANCER CELLS - The present invention provides for assays useful in predicting whether a cancer patient risks suffering erythropoietin-induced tumor progression if treated with erythropoietin. More specifically, one embodiment provides for a validated quantitative reverse transcriptase polymerase chain reaction assay that detects erythropoietin receptor expression, thus indicating whether a cancer patient risks suffering erythropoietin-induced tumor progression if treated with erythropoietin. | 2010-11-25 |
20100297640 | HAND HELD MICRO PCR DEVICE - Instant invention is about a hand held micro PCR device comprising a LTCC micro PCR chip comprising a heater, a reaction chamber to load a sample. It also comprises a heater control to regulate the heater on basis of input received from a temperature sensor. It further has an optical system having an optical fiber to detect a fluorescence signal from the sample, and at least one communication interface to interact with other device(s). | 2010-11-25 |
20100297641 | METHYLATION ALTERED DNA SEQUENCES AS MARKERS ASSOCIATED WITH HUMAN CANCER - There is disclosed 103 novel methylation-altered DNA sequences (“marker sequences”) that have distinct methylation patterns in cancer, compared to normal tissue. In many instances, these marker sequences represent novel sequences not found in the GenBank data base, and none of these marker sequences have previously been characterized with respect to their methylation pattern in human cancers including, but not limited to those of bladder and prostate. These 103 sequences have utility as diagnostic, prognostic and therapeutic markers in the treatment of human cancer, and as reagents in kits for detecting methylated CpG-containing nucleic acids. | 2010-11-25 |
20100297642 | METHOD FOR DETERMINING FRAMESHIFT MUTATIONS IN CODING NUCLEIC ACIDS - The present invention relates to a method for identifying frameshift mutations in coding nucleic acid sequences. | 2010-11-25 |
20100297643 | Terminus-Specific DNA Modification Using Random-Sequence Template Oligonucleotides - A method is provided for analyzing DNA molecules having unknown 3′ terminal sequences. The method involves contacting a DNA molecule with a plurality of template oligonucleotides blocked at their 3′ termini such that the template oligonucleotides are not extendable by DNA polymerase. The 3′ proximal portions of each of the template oligonucleotides comprise a region of random sequence and the 5′ proximal portions of each of the template oligonucleotides comprise the complement of a tag sequence. The DNA molecule and the template oligonucleotides are combined under conditions wherein the 3′ terminus of the DNA molecule hybridizes to the 3′ proximal portion of a template oligonucleotide and is extended by a DNA polymerase to produce a DNA molecule comprising a 3′ terminal tag sequence, and wherein the template oligonucleotide is not extended. | 2010-11-25 |
20100297644 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY SPACING - Nucleic acid sequencing methods and related devices, products and kits are disclosed. Methods for sequencing a target nucleic acid comprise providing a daughter strand produced by a template-directed synthesis, the daughter strand comprising a plurality of subunits coupled in a sequence corresponding to a contiguous nucleotide sequence of all or a portion of the target nucleic acid, wherein the individual subunits comprise a probe and a reporter construct. The subunit encodes sequence information in its reporter construct that is less than sequence information in the corresponding portion of the target nucleic acid. The reduced information allows for reduced resolution requirements on the detection system and for increased size of resolvable reporter groups. | 2010-11-25 |
20100297645 | AUTOMATIC DETECTION OF INFECTIOUS DISEASES - The invention relates to the detection of infectious diseases. A system for automatic detection of infectious diseases is disclosed. The system comprises an input unit for receiving a blood sample, a lysis unit, a PCR unit, a sample unit and a detection unit. The systemmay based on an inputted blood sample generate an output signal that isindicative of the presence of pathogen DNA in the blood sample. | 2010-11-25 |
20100297646 | METHOD FOR DETECTION OF CANCER - A method for detecting a cancer(s) based on an expression of prescribed polypeptides is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing in serum derived from cancer-bearing living body. Because these polypeptides react with antibodies specifically existing in serum of a cancer patient, cancers in a living body can be detected by measuring the antibody in a sample. Cancers in a living body can also be detected by measuring the antigen protein of the antibody per se or mRNA encoding it. | 2010-11-25 |
20100297647 | POLYMERASE-BASED SINGLE-MOLECULE SEQUENCING - The invention relates to an assay method for determining the base sequence in a nucleic acid sample which comprises detection of a single base in said sequence using a polymerase modified to include at least one fluorophore and a dark quencher group; detecting and deducing the amount of energy transfer. | 2010-11-25 |
20100297648 | METHOD FOR DIAGNOSING SUSCEPTIBILITY TO POST-TRAUMATIC SCAR-TISSUE FORMATION - Disclosed is an in vitro method for diagnosing susceptibility to post-traumatic scar tissue formation, wherein from a biological sample of a patient the nucleotide of the -509 position of the TGF-β1 gene is determined and if said -509 position contains exclusively C, thus it is the homozygotic wild type allele, then said patient is considered to be susceptible to post-traumatic scar tissue formation. The invention relates furthermore to diagnostic kits for the detection of susceptibility to post-traumatic scar tissue formation, preferably for the detection of susceptibility to tracheal stenosis from a biological sample. | 2010-11-25 |
20100297649 | METHODS AND MATERIALS FOR DETECTING GENE AMPLIFICATION - This document relates to methods and materials involved in detecting gene amplification in a mammal. For example, methods and materials for detecting amplification at CPM and MDM2 loci to determine the presence or absence of a malignant lipomatous neoplasm in a mammal are provided. | 2010-11-25 |
20100297650 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 193P1E1B USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene 0193P1E1B (also designated 193P1E1B) and its encoded protein, and variants thereof, are described wherein 193P1E1B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 193P1E1B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 193P1E1B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 193P1E1B can be used in active or passive immunization. | 2010-11-25 |
20100297651 | Methods of Modulating Vesicular Trafficking - Described are methods of identifying compounds useful for modulating vesicular trafficking, particularly those that disrupt the interactions between ARNO and the V-ATPase a2-subunit. Also described are peptides that modulate vesicular trafficking. | 2010-11-25 |
20100297652 | MIRNA BIOMARKERS OF PROSTATE DISEASE - This application describes miRNAs that may be used as serum or plasma biomarkers for characterizing prostate disease in a patient. These miRNA biomarkers may be used alone or in combination with other markers for the diagnosis, prognosis, or monitoring of diseases such as prostate cancer. | 2010-11-25 |
20100297653 | METHODS OF DIAGNOSING AND TREATING CANCER - The invention features methods of evaluating the risk of cancer recurrence in a subject diagnosed with cancer. | 2010-11-25 |
20100297654 | THREE-COMPONENT BIOSENSORS FOR DETECTING MACROMOLECULES AND OTHER ANALYTES - The invention generally provides three-component molecular biosensors. The molecular biosensors are useful in several methods including in the identification and quantification of target molecules. | 2010-11-25 |
20100297655 | SOCS-1 GENE METHYLATION IN CANCER - Methods are provided for identifying a cell exhibiting unregulated growth associated with methylation-silenced transcription of a suppressor of cytokine signaling (SOCS)/cytokine-inducible SH2 protein (CIS) family member (SOCS/CIS) gene such as the SOCS-1 gene. In addition, methods of treating a cancer patient, wherein cancer cells in the patient exhibit methylation-silenced transcription of SOCS/CIS gene such as a SOCS-1 gene, are provided, as are reagents for practicing such methods. | 2010-11-25 |
20100297656 | AMPLICON MELTING ANALYSIS WITH SATURATION DYES - Methods are provided for nucleic acid analysis wherein a target nucleic acid that is at least partially double stranded is mixed with a dsDNA binding dye having a percent saturation of at least 50% to form a mixture. In one embodiment, the nucleic acid is amplified in the presence of the dsDNA binding dye, and in another embodiment a melting curve is generated for the target nucleic acid by measuring fluorescence from the dsDNA binding dye as the mixture is heated. Dyes for use in nucleic acid analysis and methods for making dyes are also provided. | 2010-11-25 |
20100297657 | EXPRESSION PROFILE OF PROSTATE CANCER - The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of prostate cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications. | 2010-11-25 |
20100297658 | DETECTING METHYLATED MAMMALIAN NUCLEIC ACID IN STOOL - This document includes methods and materials for enriching and detecting cancer markers. For example, this document includes methods and materials for enriching methylated mammalian nucleic acid from stool samples. | 2010-11-25 |
20100297659 | THIN-FILM LAYERED CENTRIFUGE DEVICE AND ANALYSIS METHOD USING THE SAME - Disclosed herein is a thin-film layered centrifuge device and an analysis method using the same. One example of an embodiment of the present invention is a thin film layered centrifuge device where a device, such as a lab on a chip, a protein chip and a DNA chip, for diagnosing and detecting a small amount of material in a fluid is integrated into a rotatable thin-film layered body, and to an analysis method using the thin-film layered centrifuge device. | 2010-11-25 |
20100297660 | SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH RENAL DISEASE - Methods for determining the genetic predisposition of a human subject to developing renal disease, such as focal segmental glomerulosclerosis (FSGS) or end-stage kidney disease are provided herein. These methods include methods for detecting renal disease, or determining the risk of developing renal disease in a human subject, such as a subject of African ancestry. The methods utilize the detection of one or more haplotype blocks comprising at least two tag single nucleotide polymorphisms (SNPs) in a non-coding region of a MYH9 gene or detecting the presence of at least one tag SNP in a non-coding region of a MYH9 gene. An array for detecting a genetic predisposition to renal disease using probes complementary to the tag SNPs in the non-coding region of the MYH9 gene are also disclosed. | 2010-11-25 |
20100297661 | Diagnostic Composition and Kit for Renal Cell Carcinoma - Disclosed herein are a composition and a kit for diagnosing renal cell carcinoma. The composition and kit employ, as a renal cell carcinoma marker, nicotinamide N-methyltransferase, L-plastin, secretagogin, NM23A, CapG, which is an actin regulatory protein, and/or C4a anaphylatoxin. | 2010-11-25 |
20100297662 | ANTIBODY AND USE THEREOF - An antibody provided by the present invention has a low reactivity with amyloid precursor proteins, and has a higher reactivity with amylospheroids than with amyloid β fibrils or monomeric amyloid β-proteins. According to the present invention, an antibody is provided that has a higher reactivity with amylospheroids than with amyloid precursor proteins, and has any one or more of the following properties: (i) a higher activity with amylospheroids than with amyloid β fibrils; (ii) a higher reactivity with amylospheroids than with monomeric amyloid β-proteins; and (iii) an activity of inhibiting neuronal cell death induced by amylospheroids. | 2010-11-25 |
20100297663 | METHODS AND SYSTEMS FOR ASSAYING, MAINTAINING, AND ENHANCING THE ACTIVITY OF THE IMMUNE SYSTEM OF A SUBJECT - A method for non-invasively assessing a subject's health includes evaluating a state of a subject's immune response. Such a method may include obtaining a salivary sample from the subject and assaying the salivary sample for IgA. The state of a component of the subject's immunity may be evaluated in conjunction with the administration of one or more substances known to elicit a cell-mediated immune response to the subject to determine the effect of the one or more substances on the subject's humoral, or antibody-mediated, immune response. Assay methods may also be used to optimize the dosage of an immune support component to be administered to a particular subject. Systems that include assays for evaluating the state of a subject's immune response and nutraceuticals are also disclosed. | 2010-11-25 |
20100297664 | PARATOPE AND EPITOPE OF ANTI-MORTALIN ANTIBODY - The amino acid sequences of paratope regions involved in internalizing function of an anti-mortalin antibody into tumor cells were determined for the L-chain and H-chain variable regions of cellular internalizing anti-mortalin antibodies and non-internalizing anti-mortalin antibodies. Cancer-cell-specific drug delivery is provided by using the mortalin-binding activity of a single-chain antibody (scFv) wherein L-chain and H-chain variable regions both having the paratope region are linked together via a peptide linker. Also, the sequence of 6 amino acids of an epitope to be recognized by an anti-mortalin antibody having the internalizing function was determined. With the use of an expression vector comprising a nucleic acid that encodes the epitope, an agent for accelerating internalization of a mortalin antibody, a drug bound thereto, and the like into cancer cells is provided. | 2010-11-25 |
20100297665 | METHOD FOR TESTING AND SCREENING P38 MAP KINASE MODIFIERS - This invention provides methods for treating diseases associated with elevated p38 mitogen-activated protein kinase activity. Moreover, the invention provides methods for testing a candidate compound for a p38 mitogen-activated protein kinase modifying activity by calculating the level of relocalization of an SMN complex component from the cytoplasm to the nucleus of a cell. Additionally, the invention provides a kit and a system for calculating the same. | 2010-11-25 |
20100297666 | METHODS FOR DETERMINATION OF PROTEIN PHOSPHATASE ACTIVITY, AND USES IN PREDICTING THERAPEUTIC OUTCOMES - One aspect of the present disclosure encompasses methods for determining a protein kinase or phosphatase activity in a biological sample, comprising: contacting in a reaction mix a first test sample and a fluorescently-labeled peptide substrate capable of being modified by a protein phosphatase or a protein kinase, contacting the reaction mix with a TiO | 2010-11-25 |
20100297667 | METHOD FOR DIAGNOSIS OF DISEASE USING QUANTITATIVE MONITORING OF PROTEIN TYROSINE PHOSPHATASE - The present invention relates to a method for quantifying protein tyrosine phosphatase (referred as PTP hereinafter) in biosamples, precisely a diagnostic method for disease by quantifying PTP using mass spectrometry and profiling of comparative PTP levels. By quantifying PTP in biosamples and profiling thereof according to the method of the present invention, disease can be diagnosed and diverse disease conditions and health conditions can be confirmed via profiling. | 2010-11-25 |
20100297668 | HUMAN E3ALPHA UBIQUITIN LIGASE FAMILY - The present invention relates to a novel polypeptide encoding a protein which is the full length human ortholog of E3α ubiquitin ligase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for these and related products. | 2010-11-25 |
20100297669 | NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 191P4D12(b) USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene 191P4D12(b) and its encoded protein, and variants thereof, are described wherein 191P4D12(b) exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 191P4D12(b) provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 191P4D12(b) gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 191P4D12(b) can be used in active or passive immunization. | 2010-11-25 |
20100297670 | METHODS FOR DETECTION OF IMMUNOSUPPRESSANT DRUGS - Methods and reagents are disclosed for enhancing the bioavailability of a hydrophobic drug, and in some embodiments for determining a hydrophobic drug, in a sample suspected of containing a hydrophobic drug. A combination is formed in a medium where the combination comprises the sample, a hemolytic agent where a determination of the hydrophobic drug is conducted, and a bioavailability agent for the hydrophobic drug. The bioavailability agent comprises an ionic detergent comprising a chain of at least 10 carbon atoms or a non-ionic detergent comprising a chain of at least 15 repeating ethylene oxide units or propylene oxide units or a combination of ethylene oxide units and propylene oxide units. The concentration of the bioavailability agent in the medium is sufficient to enhance the bioavailability of the hydrophobic drug. The medium is incubated under conditions for enhancing the bioavailability of the hydrophobic drug, and in a determination of the hydrophobic drug under conditions for hemolyzing cells in the sample. For determination of the hydrophobic drug, reagents for determining the presence and/or amount of the hydrophobic drug in the sample are added to the medium. The reagents comprise at least one antibody for the hydrophobic drug. The medium is examined for the presence of a complex comprising the hydrophobic drug and the antibody for the hydrophobic drug. The presence and/or amount of the complex indicates the presence and/or amount of the hydrophobic drug in the sample. | 2010-11-25 |
20100297671 | Method and Device for the Quantitative Determination of Analytes in Liquid Samples - The invention relates to a method and a device for the highly sensitive parallel detection and quantitative determination of analytes in liquid samples. According to said method, total internal reflection fluorescence (TIRF) is used in combination with a binding inhibition test on a specially coated support. The inventive method makes it possible to quickly analyze different types of liquids, such as drinking water, fruit juices, milk, serum, blood plasma, urine, etc., while allowing samples to be analyzed simultaneously regarding several different analytes, including hormones, antibiotics, pesticides, pharmaceuticals, drugs, and other molecules or molecular complexes, for example. | 2010-11-25 |
20100297672 | HIGHLY SENSITIVE SYSTEM AND METHODS FOR ANALYSIS OF TROPONIN - The invention provides methods, compositions, kits, and systems for the sensitive detection of cardiac troponin. Such methods, compositions, kits, and systems are useful in diagnosis, prognosis, and determination of methods of treatment in conditions that involve release of cardiac troponin. | 2010-11-25 |
20100297673 | METHODS AND COMPOSITIONS FOR UPREGULATION OF PEROXIREDOXIN ACTIVITY - A novel method of identifying compounds capable of upregulating Peroxiredoxin activity is disclosed. The method includes providing a sample of cells that express Peroxiredoxin, providing a sample of a candidate compound, contacting the cell sample and the compound sample, and measuring a quantitative indicator of Peroxiredoxin activity within the cell sample after the contacting step. Peroxiredoxin inducers identified by the method and uses therefore to upregulate Peroxiredoxin activity in subjects and to reduce LDL and/or VLDL levels and to prevent or treat atherosclerosis and inflammatory disorders such as arthritis in subjects are also described. The invention also provides a method of treatment of inflammatory and cardiovascular diseases which comprises providing a patient in need of treatment with an effective amount of a composition that increases Peroxiredoxin protein or activity. | 2010-11-25 |
20100297674 | NOVEL CELL LINES EXPRESSING NaV AND METHODS USING THEM - Cells and cell lines that express voltage-gated sodium ion channels (NaV) and methods for using the cells and cell lines are disclosed herein. The NaV-expressing cells and cell lines are useful in high throughput screening assays. | 2010-11-25 |
20100297675 | SUBSTRATE AND METHOD FOR CULTURING BREAST CELLS - A cell culture article includes a porous substrate having a plurality of pores and a plurality of interstices in communication with the pores. At least some of the plurality of pores and interstices are sufficiently large for two or more mammary epithelial cells to cluster within the pores or interstices. Non-malignant mammary epithelial cells or breast cancer cells may not attach strongly to the substrate surface, which may encourage cell-cell interaction. In many cases, the article is desirably free of components of unknown origin. The articles may be capable of maintaining culture of malignant and non-malignant mammary epithelial cells and allowing for development of in vivo-like morphologies or characteristics of such cells. | 2010-11-25 |
20100297676 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT - This invention is directed to methods and compositions for diagnosis, prognosis and for determining methods of treatment. The physiological status of a cell present in a sample (e.g. clinical sample) can be used in diagnosis or prognosis of a condition (e.g. Chronic Lymphocytic Leukemia), in patient selection for therapy, to monitor treatment and to modify or optimize therapeutic regimens. | 2010-11-25 |
20100297677 | CYCOCHROME C SYNTHESIS INHIBITORS - The invention provides methods for identifying a compound that inhibits cytochrome c synthesis. This invention further provides a method for the high throughput screening of compounds that inhibit cytochrome c synthesis. | 2010-11-25 |
20100297678 | BIOMARKERS FOR MULTIPLE SCLEROSIS - The present invention relates to the diagnosis of neurological disorders, more specifically to the diagnosis of multiple sclerosis. A biomarker panel is provided which can be used to detect if a subject has multiple sclerosis. Also described are methods of identification of such biomarkers. | 2010-11-25 |
20100297679 | IDENTIFICATION AND QUANTIFICATION OF BIOMARKERS FOR EVALUATING THE RISK OF PRETERM BIRTH - Described herein are methods for evaluating the risk of preterm birth in pregnant subjects. The methods involve detecting and quantifying one or more biomarkers associated with preterm birth in a biological sample from the subject. Also described herein are isolated biomarkers and kits useful in predicting the risk of preterm birth. | 2010-11-25 |
20100297680 | METHODS FOR ASSESSING THE RISK FOR DEVELOPMENT OF CARDIOVASCULAR DISEASE - The present invention relates to diagnostic tests, methods and kits that are useful to assess a subject's risk of developing a pathologic condition related in part to the presence of HDL oxidation product. Measuring the quantity of one or more HDL oxidation products present in the blood is useful in evaluating risk for developing or evaluating the severity of a disease or evaluating response to treatment for such a disease as, for instance, cardiovascular disease. | 2010-11-25 |
20100297681 | FLUORESCENT PROBE FOR MEASUREMENT OF GLUCURONATE TRANSFERASE - A fluorescent probe for measurement of UDP-glucuronosyltransferase, which comprises a fluorescein derivative, wherein in the fluorescein derivative, the 2-carboxy group on the benzene ring of fluorescein is replaced with another monovalent substituent, provided that said substituent is a substituent other than sulfo group, and the substituent does not have carboxy group or sulfo group, and wherein the fluorescein derivative may have an arbitrary substituent at a position on the benzene ring other than the 2-position, and the fluorescein derivative may have a substituent selected from the group consisting of an alkoxy group and a halogen atom at the 2-position and/or the 7-position of fluorescein. | 2010-11-25 |
20100297682 | METHOD OF DIAGNOSTIC RHEUMATOID ARTHRITIS BY SUGAR CHAIN ANALYSIS - Provided is a novel method of diagnosing rheumatoid arthritis. Based on the quantitative expression profile of sugar chain expression amount in the serum (whole serum, HAP or LAP), the relevancy thereof to rheumatoid arthritis is analyzed. As a result, a sugar chain and a glycoprotein showing a change depending on the onset of rheumatoid arthritis are found out and thus a serum sugar chain and a glycoprotein usable as a novel biomarker are provided. | 2010-11-25 |
20100297683 | METHOD - The present invention provides a method for the detection of a protease comprising the use of a substrate partially coated with a film of a synthetic polymeric matrix comprising a peptide of up to 20 amino acids. Apparatus for performing such methods is also disclosed. | 2010-11-25 |
20100297684 | ACTIVATIBLE DYES - Novel, activatable dyes, such as photoactivatable dyes, e.g., oxazine dyes, are described. Some of the dyes are targeting dyes that can, e.g., target biomolecules, such as polypeptides, proteins, or nucleic acids. Upon activation, such as by irradiation, the novel dyes rapidly turn on their fluorescence and emit light, such as near-IR light with spatial and temporal precision. | 2010-11-25 |
20100297685 | METHODS FOR CULTURING AND ANALYZING CELLS - The present invention generally relates to methods for culturing and analyzing cells using liquid bridges. | 2010-11-25 |
20100297686 | DEVICES FOR INTRACELLULAR SURFACE-ENHANCED RAMAN SPECTROSCOPY - Provided are surface-enhanced Raman spectroscopy (SERS) devices suitable for intra-subject (e.g., intracellular) observation, which devices may be of nanoscale size. Also provided are related SERS analysis methods. | 2010-11-25 |
20100297687 | DETECTION AND MEASUREMENT OF MASS CHANGE USING AN ELECTROMECHANICAL RESONATOR - A change in impedance of a electromechanical resonating sensor is utilized to detect and/or measure a change in mass accumulated on the sensor. The impedance is monitored at a fixed frequency. The fixed frequency may be at or near the resonance frequency of the sensor. In various configurations, the sensor comprises a quartz crystal microbalance sensor or a piezoelectric cantilever sensor. | 2010-11-25 |
20100297688 | METHOD FOR DIAGNOSING OR PREDICTING SHORT STATURE IN HUMANS - An improved assay for measuring the release of endogenous growth hormone (GH) is described. The method focuses on determining the presence of an immediate release pool (IRP) of GH, and the extent to which it is rapidly discharged into the circulation of humans, including children. A larger and less labile pool responds continuously to long term stimulation. The method considers that determining the ten minute AUC measurement, i.e., ten minutes after induction of GH release by administering growth hormone releasing hormone (GHRH) will reveal an immediate release pool of GH. As further disclosed herein, the IRP of GH has a higher correlation with peak GH release than the conventional 120 minute time point. Further the AUC | 2010-11-25 |
20100297689 | PLACENTAL STEM CELL POPULATIONS - The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting. | 2010-11-25 |
20100297690 | Detection of salmonella lactose+ - The invention relates to a medium for the detection and/or identification of | 2010-11-25 |
20100297691 | DEVICES AND PROCESSES FOR COLLECTING AND CONCENTRATING SAMPLES FOR MICROBIOLOGICAL ANALYSIS - The present invention refers to manual devices for the collecting and concentrating liquid samples for microbiological analysis and their respective methods of use. The manual devices comprise a body which contains a sample, a removable support, a microporous membrane, and a plunger. The present invention is also directed to methods of collecting and concentrating of liquid samples onto a microporous membrane for micro-biological analysis. | 2010-11-25 |
20100297692 | REACTION MEDIUM FOR DETECTING AND/OR IDENTTIFYING STAPHYLOCCOUS AUREUS - A reaction medium for characterizing | 2010-11-25 |
20100297693 | Production of carrier-peptide conjugates using chemically reactive unnatural amino acids - Provided are methods of making carrier polypeptide that include incorporating a first unnatural amino acid into a carrier polypeptide variant, incorporating a second unnatural amino acid into a target polypeptide variant, and reacting the first and second unnatural amino acids to produce the conjugate. Conjugates produced using the provided methods are also provided. In addition, orthogonal translation systems in methylotrophic yeast and methods of using these systems to produce carrier and target polypeptide variants comprising unnatural amino acids are provided. | 2010-11-25 |
20100297694 | NOVEL GENE FROM HANCENULA POLYMORPHA CAPABLE OF CONTROLLING UNFOLDED PROTEIN RESPONSE AND METHOD FOR INCREASING EFFECT OF SECRETION USING THE SAME - The present invention relates to a novel | 2010-11-25 |
20100297695 | Nucleic Acids Encoding Chimeric CD154 Polypeptides - The present invention provides for an isolated polynucleotide sequence encoding a chimeric CD154, comprising a first nucleotide sequence encoding an extracellular subdomain of non-human CD154, preferably murine CD154, that replaces a cleavage site of human CD154, and a second nucleotide sequence encoding an extracellular subdomain of human CD154 that binds to a human CD154 receptor. The present invention also provides for the chimeric CD154 that is encoded by the above-described polynucleotide sequence, an expression vector and a genetic vector comprising the polynucleotide sequence, a host cell comprising the expression vector or the genetic vector, a process for producing the chimeric CD154, and methods for utilizing the expression vectors and genetic constructs containing the chimeric CD154 polynucleotide sequences. | 2010-11-25 |
20100297696 | Enzyme Production in Culture Medium Comprising Raw Glycerol - The present invention is directed to a method of producing desired proteins from a host cell grown in a media comprising raw glycerol as a carbon source. | 2010-11-25 |
20100297697 | METHODS FOR INCREASING PROTEIN TITERS - The invention relates to methods of increasing the titre of a protein of interest in a cell as well as the improved production and purification of optimised biomolecules, one component of which is the domain C | 2010-11-25 |
20100297698 | SYSTEM AND METHOD FOR PRODUCING SYNTHETIC MICROORGANISMS CAPABLE OF TRANSLATING PROTEINS CONTAINING NON-STANDARD AMINO ACIDS - The disclosed invention relates to the generation of host cells containing rare codons and/or absent tRNAs, and the use of orthogonal tRNA systems that can insert a non-standard amino acid into a growing peptide chain. This invention combined with the capacity to synthesize whole genomes has important implications in synthetic biology, as it allows the rewriting of the genetic code of existing or newly designed organisms. | 2010-11-25 |